Awards Categories

Applicable to those primary R&D companies undertaking new medicines research and yet to have their lead programme/s enter clinical development

Criteria

• Level of Innovation – How does the innovation represent a potentially meaningful advancement over existing treatments?
• Impact on Patient Outcomes – What is the potential or demonstrated impact on patient outcomes?
•  Financing & Deals – How has the company been funded to date and what business development deals have been secured?
• Leadership – What is the expertise and experience of the executive leadership team and Board of Directors and or Scientific Advisory Board?
• ESG – How has the company considered diversity at all levels of the team, supported entrepreneurship and promotion of science in its community and what steps have been taken to minimise the environmental impact of its operations?

Applicable to those primary R&D companies undertaking new medicines research where their lead programme/s have entered the clinical development stages, whether directly sponsored by them or via a partnering deal.

Criteria

• Level of Innovation – How does the innovation represent a potentially meaningful advancement over existing treatments?
• Impact on Patient Outcomes – What is the potential or demonstrated impact on patient outcomes?
•  Financing & Deals – How has the company been funded to date and what business development deals have been secured?
• Leadership – What is the expertise and experience of the executive leadership team and Board of Directors and or Scientific Advisory Board?
• ESG – How has the company considered diversity at all levels of the team, supported entrepreneurship and promotion of science in its community and what steps have been taken to minimise the environmental impact of its operations?

Applicable to those companies and institutions who are deploying a leading-edge technology to enable the discovery and or development of innovative therapeutic treatments or healthcare technologies.

Criteria

• Level of Innovation – How is the technology or its application differentiated from existing methodologies?
• Impact on Patient Outcomes – How will the technology enable development or adoption to improve patient access to innovative treatments to improve outcomes?
• Financing & Deals – How has the development of the technology been funded to date and what external collaborations or licensing deals have been secured?
• Leadership – What is the expertise and experience of the executive leadership team in commercialising an innovative technology?
• ESG – How has the company considered diversity in benefit of the technology and within the team, supported entrepreneurship and considered the environmental impact of its development?

Applicable to those primary R&D companies undertaking research and development of a new health technology product or service, including diagnostics, patient stratification, drug delivery and digital health

Criteria

• Level of Innovation – How is the proprietary product or technology or its application differentiated from existing methodologies?
• Impact on Patient Outcomes – How will the technology improve patient outcomes?
• Financing & Deals – How has the company been funded to date and what external collaborations or licensing deals have been secured?
• Leadership – What is the expertise and experience of the executive leadership team and Board of Directors and or Scientific Advisory Board?
• ESG – How has the company considered diversity in benefit of their technology and within the team, supported entrepreneurship and considered the environmental impact of its development?

Applicable to those charged with commercialisation of a non-profit institution’s intellectual property where the nominated may include a spin-out company formation, licensing deal, collaboration or other mechanism that supports translation of the academic research towards development.

Criteria

• The Deal – What have been the highlight features of the deal?
• Level of science and technology innovation – How does the innovation represent a potentially meaningful advancement over existing treatments or new medicine discovery approaches?
• Level of business innovation – how have the parties involved innovatively addressed any key commercial terms in the deal?
• Equitable reward – How have, or could, the academic researchers involved in the programme benefit if the programme is successful?
• ESG – How have the parties considered diversity, supported entrepreneurship and mitigated the environmental impact of the programme?

Objective

Highlighting exceptional organisations that deliver high-quality, reliable R&D services, empowering life science companies to achieve their goals.

Criteria

• How has the company developed or adopted innovation into the services provided? 
• How has the company demonstrated flexible support to nascent Life Science companies? 
• How has the company provided leadership in the sector?   
• How has the company collaborated with the academia to enable translational research and or scientific publications? 
• How would you describe the company’s ESG strategy and how the impact is seen? 

Objective
Showcasing service providers whose forward-thinking solutions and business approach are driving client success and enabling innovation.

Criteria

• How does the company provide a unique, differentiated service offering to solve a sector challenge?  
• How has the above approach impacted the company’s standing in the sector to date? 
• How does the company support growth in the ecosystems in which they operate? 
• How does the company encourage and enable entrepreneurship? 
• How do you encourage diversity, equality and inclusion in your organisation? 

Objective
To recognise excellence and innovation in the provision of laboratory and or office space to accommodate research and development companies enabling growth and sustainability.

Criteria

• How has the Provider created an innovation-friendly workspace, encouraging idea exchange beyond individual occupiers? 
• How has the Provider supported its occupiers through uncertain financing times? 
• How has the Provider supported growth of the wider Life Science sector? 
• How has the Provider supported entrepreneurship and the promotion of science in society? 
• How has the Provider considered and mitigated the environment impact of the facilities creation and operation?  

Objective
Celebrating individuals whose energy, generosity and connections strengthen collaboration and opportunity throughout the ecosystem whilst not being an evet organiser.

Criteria

• How does the individual demonstrate consistent engagement in networking activities? 
• How has the individual demonstrated generosity in sharing advice, experience and contacts? 
• Is the individual recognised as a connector of people, opportunities and ideas within their network? 
• What characteristics does the individual display to build authentic, long-term professional relationships? 
• Does the individual demonstrate support of others without a focus on self-promotion or selling? 

Objective
Honouring an early career leader who is making remarkable progress and contribution to shaping the future of life science.

Criteria

• How has the individual shown significant contribution to advancing science, innovation, or business growth? 
• How has the person demonstrated influence leadership, or inspiration of peers? 
• How do the future career plans of the individual suggest increasing leadership and influence in the life sciences sector? 
• Has the person received any formal recognition from within their community or network? 
• What activities does the individual undertake to promote careers in life sciences?